Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. METHODS: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. RESULTS: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P<0.001 for both comparisons). Continuous lenalidomide-dexamethasone was superior to MPT for all secondary efficacy end points, including overall survival (at the interim analysis). Overall survival at 4 years was 59% with continuous lenalidomide-dexamethasone, 56% with 18 cycles of lenalidomide-dexamethasone, and 51% with MPT. Grade 3 or 4 adverse events were somewhat less frequent with continuous lenalidomide-dexamethasone than with MPT (70% vs. 78%). As compared with MPT, continuous lenalidomide-dexamethasone was associated with fewer hematologic and neurologic toxic events, a moderate increase in infections, and fewer second primary hematologic cancers. CONCLUSIONS: As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation. (Funded by Intergroupe, Francophone du Myélome and Celgene; FIRST ClinicalTrials.gov number, NCT00689936; European Union Drug Regulating Authorities Clinical Trials number, 2007-004823-39.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“However, the incidence of grade 3 or 4 infections was 29% with lenalidomide and dexamethasone in the primary analysis of the FIRST trial,5 which was consistent with the incidence in our trial (32.1% in the daratumumab group and 23.3% in the control group).”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“In this subset of patients, maintenance therapy with proteasome inhibitors alone or in combination with lenalidomide seems to be more effective than single-agent lenalidomide34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“Patients with high-risk cytogenetic features might be the only exception, although they do derive a progression-free survival (PFS) benefit34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“The most worrisome adverse effect observed in studies of lenalidomide maintenance therapy is an up to six-fold increase in the risk of second primary malignancies, in particular, MDS and acute myeloid leukaemia (AML): 5.3% versus 0.8% with placebo or observation34.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Self-citationBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationGroup sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citation
Cited by
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
“t(4;14) or t(14;16) translocation or 17p deletion 44/256 46/259”
BackgroundSelf-citationKumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177
Self-citationOral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060
“Back pain 87 (24) 3 (<1) 0 62 (17) 9 (3) 0”
Self-citationDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Self-citationProteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Self-citationSonneveld, P., Avet-Loiseau, H., Lonial, S., Usmani, S., Siegel, D., Anderson, K. C., Chng, W.-J., Moreau, P., Attal, M., Kyle, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-01-631200 · Cited by 928
Self-citationDurie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., San Miguel, J., Sonneveld, P., Mateos, M. V., Zamagni, E., Avet-Loiseau, H., Hajek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 877
“The two following options are recommended based on data from randomised phase III trials [I, A]: bortezomib (administered subcutaneously)/melphalan/prednisone (VMP) [11] or lenalidomide plus low-dose dexamethasone (Rd) [12]; both VMP and Rd are approved in this setting by the European Medicines Agency (EMA).”
BackgroundMethodSelf-citationMultiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Palumbo, A., Bringhen, S., Mateos, M.-V., Larocca, A., Facon, T., Kumar, S. K., Offidani, M., McCarthy, P., Evangelista, A., Lonial, S., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615187 · Cited by 775
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationMcCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
“Mean, months (range)§ 30 (0-108) 13 (0-51) 25 (0-61) 25 (0-55) 39 (27-55) 20 (0-49) 35 (2-71) 29 (0-75) 28 (0-108) 22 (0-86)”
Self-citationGirmenia, C., Cavo, M., Offidani, M., Scaglione, F., Corso, A., Di Raimondo, F., Musto, P., Petrucci, M. T., & Barosi, G. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.01.001 · Cited by 662
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 456
Multiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 355
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
“Lenalidomide has remarkable activity in patients with newly diagnosed MM (91) and relapsed refractory MM (92, 93) and it has contributed to significantly improved survival of myeloma patients (94).”
BackgroundJackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Hockaday, A., Jones, J. R., Kishore, B., Garg, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30687-9 · Cited by 348
Malard, F., Neri, P., Bahlis, N. J., Terpos, E., Moukalled, N., Hungria, V. T. M., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 337
Self-citationThe proteasome and proteasome inhibitors in multiple myeloma
Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Anderson, K. C., & Richardson, P. G. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9707-8 · Cited by 340
Self-citationTreatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Mikhael, J., Ismaila, N., Cheung, M. C., Costello, C., Dhodapkar, M. V., Kumar, S., Lacy, M., Lipe, B., Little, R. F., Nikonova, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02096 · Cited by 331
“gov identifier: NCT00689936) in transplant-ineligible patients.(40) Continuous lenalidomide-dexamethasone was also associated with an improvement in OS compared with MPT.”
BackgroundMethodResultMultiple myeloma: patient outcomes in real‐world practice
Yong, K., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., Raab, M. S., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14213 · Cited by 326
“New regimens and treatment sequences have ultimately improved outcomes (Benboubker et al, 2014; San-Miguel et al, 2014; Stewart et al, 2015).”
BackgroundSelf-citationTrends in overall survival and costs of multiple myeloma, 2000–2014
Fonseca, R., Abouzaid, S., Bonafede, M., Cai, Q., Parikh, K., Cosler, L., & Richardson, P. (2017) · Leukemia · doi:10.1038/leu.2016.380 · Cited by 323
Frontline therapy of multiple myeloma
Moreau, P., Attal, M., & Facon, T. (2015) · Blood · doi:10.1182/blood-2014-09-568915 · Cited by 244
Self-citationIsatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Facon, T., Dimopoulos, M.-A., Leleu, X. P., Beksac, M., Pour, L., Hájek, R., Liu, Z., Minarik, J., Moreau, P., Romejko-Jarosinska, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400712 · Cited by 284
Self-citationMultiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Costello, C., Efebera, Y., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 277
Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., et al. (2018) · Blood · doi:10.1182/blood-2017-07-795047 · Cited by 271
Self-citationSpencer, A., Lentzsch, S., Weisel, K., Avet-Loiseau, H., Mark, T. M., Spicka, I., Masszi, T., Lauri, B., Levin, M.-D., Bosi, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194118 · Cited by 263
Self-citationKumar, S. K., Berdeja, J. G., Niesvizky, R., Lonial, S., Laubach, J. P., Hamadani, M., Stewart, A. K., Hari, P., Roy, V., Vescio, R., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71125-8 · Cited by 262
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 255
“The incidence of SPMs was 3% in patients on continuous lenalidomide/dexamethasone, 6% in the 18-cycle group, and 5% in the MPT group [188].”
Facon, T., Dimopoulos, M. A., Meuleman, N., Belch, A., Mohty, M., Chen, W.-M., Kim, K., Zamagni, E., Rodriguez-Otero, P., Renwick, W., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0539-0 · Cited by 238
Self-citationThe Diagnosis and Treatment of Multiple Myeloma
Gerecke, C., Fuhrmann, S., Strifler, S., Schmidt-Hieber, M., Einsele, H., & Knop, S. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0470 · Cited by 233
Dimopoulos, M. A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C. K., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33003-4 · Cited by 237
Self-citationInterpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Richardson, P. G., San Miguel, J. F., Moreau, P., Hajek, R., Dimopoulos, M. A., Laubach, J. P., Palumbo, A., Luptakova, K., Romanus, D., Skacel, T., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0141-0 · Cited by 228
Self-citationMultiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 209
“Rd which combines lenalidomide with a lower dose of dexamethasone (40 mg once weekly) is an active regimen in newly diagnosed multiple myeloma, and has less toxicity and better OS than lenalidomide plus high dose dexamethasone or MPT.58,87 Currently Rd is recommended mainly for patients who are unable to tolerate a tr…”
BackgroundMethodInfluentialNCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0002 · Cited by 202
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30124-3 · Cited by 193
Self-citationNovel agents in the treatment of multiple myeloma: a review about the future
Naymagon, L., & Abdul-Hay, M. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0282-1 · Cited by 176
“Patients ineligible for ASCT should still be evaluated for induction with lenalidomide, bortezomib, or an alkylating agent-based regimen [28, 29].”
BackgroundVogler, S., Vitry, A., & Babar, Z.-U.-D. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00449-0 · Cited by 175
Treatment of relapsed and refractory multiple myeloma
Sonneveld, P., & Broijl, A. (2016) · Haematologica · doi:10.3324/haematol.2015.129189 · Cited by 171
“trial.(17) Consequently, more patients will receive lenalidomide in first-line treatment, and this will reduce or change the number of options in relapsed MM.”
Holstein, S. A., Jung, S.-H., Richardson, P. G., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30140-0 · Cited by 173
Self-citationProgress and Paradigms in Multiple Myeloma
Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0625 · Cited by 169
Self-citationMultiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0023 · Cited by 279
O'Donnell, E. K., Laubach, J. P., Yee, A. J., Chen, T., Huff, C. A., Basile, F. G., Wade, P. M., Paba‐Prada, C. E., Ghobrial, I. M., Schlossman, R. L., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15261 · Cited by 166
Self-citationMyeloma today: Disease definitions and treatment advances
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24236 · Cited by 160
“Improved PFS and OS has been reported with a four-drug regimen of VMPT compared with VMP in a randomized phase III trial [82].”
MethodInfluentialEmerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 178
Chromosome 1q21 abnormalities in multiple myeloma
Schmidt, T. M., Fonseca, R., & Usmani, S. Z. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00474-8 · Cited by 172
Richardson, P. G. G., Jagannath, S., Moreau, P., Jakubowiak, A. J., Raab, M. S., Facon, T. T. F., Vij, R., White, D. J., Reece, D. E., Benboubker, L., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00197-0 · Cited by 158
Self-citationSecond primary malignancies in multiple myeloma: an overview and IMWG consensus
Musto, P., Anderson, K. C., Attal, M., Richardson, P. G. G., Badros, A., Hou, J., Comenzo, R. L., Du, J., Durie, B. G. M., Miguel, J. F. S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw606 · Cited by 159
Self-citationPalumbo, A., Gay, F., Cavallo, F., Di Raimondo, F., Larocca, A., Hardan, I., Nagler, A., Petrucci, M. T., Hajek, R., Pezzatti, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2466 · Cited by 150
Self-citationMultiple myeloma: the (r)evolution of current therapy and a glance into future
Gullà, A., & Anderson, K. C. (2020) · Haematologica · doi:10.3324/haematol.2020.247015 · Cited by 152
Self-citationChari, A., Martínez‐López, J., Mateos, M., Bladé, J., Benboubker, L., Oriol, A., Arnulf, B., Rodríguez‐Otero, P., Piñeiro, L., Jakubowiak, A. J., et al. (2019) · Blood · doi:10.1182/blood.2019000722 · Cited by 139
Self-citationCancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Avet‐Loiseau, H., Ludwig, H., Landgren, O., Paiva, B., Morris, C., Yang, H., Zhou, K., Ro, S. K., & Mateos, M. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.622 · Cited by 136
Self-citationUnderstanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back
Bianchi, G., & Anderson, K. C. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21252 · Cited by 165
“In combination with lenalidomide, low-dose dexamethasone improved both OS and the side-effect profile compared with high-dose dexamethasone, thus establishing low-dose dexamethasone as the preferred regimen.(71,86) Triplet therapy, such as RVD or CyBorD, can be used either in full or at a reduced dose, depending on th…”
BackgroundSelf-citationTargeting MYC in multiple myeloma
Jovanović, K., Roche‐Lestienne, C., Ghobrial, I. M., Facon, T. T. F., Quesnel, B., & Manier, S. (2018) · Leukemia · doi:10.1038/s41375-018-0036-x · Cited by 137
Self-citationFacon, T. T. F., Lee, J. H., Moreau, P., Niesvizky, R., Dimopoulos, M. A., Hájek, R., Pour, L., Jurczyszyn, A. J., Qiu, L., Klippel, Z. K., et al. (2019) · Blood · doi:10.1182/blood-2018-09-874396 · Cited by 142
Self-citationGay, F., Engelhardt, M. M., Terpos, E., Wäsch, R., Giaccone, L., Auner, H. W., Caers, J., Gramatzki, M., van de Donk, N. W. C. J., Oliva, S., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.174573 · Cited by 128
“Based on the impressive results of novel agent-based treatments in the non-transplant setting, the option of delaying ASCT until first relapse was reconsidered.(2,3,56) In all the recent randomized phase III trials comparing ASCT versus novel agent-based therapies, patients who did not receive ASCT upfront were recomm…”
BackgroundSelf-citationDimopoulos, M. A., Jakubowiak, A. J., McCarthy, P. L., Orlowski, R. Z., Attal, M., Bladé, J., Goldschmidt, H., Weisel, K. C., Ramasamy, K., Zweegman, S., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0273-x · Cited by 117
Self-citationZweegman, S., van der Holt, B., Mellqvist, U., Salomo, M., Bos, G. M. J., Levin, M., Visser-Wisselaar, H. A., Hansson, M., van der Velden, A. W. G., Deenik, W., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679415 · Cited by 124
Combination therapeutics in complex diseases
He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112
“Myeloma Lenalidomide + dexamethasone+ carfilzomib [103]; Lenalidomide + dexamethasone [104, 105]”
BackgroundSelf-citationTargeted protein degrader development for cancer: advances, challenges, and opportunities
Fang, Y., Wang, S., Han, S., Zhao, Y., Yu, C., Liu, H., & Li, N. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.03.003 · Cited by 115
Larocca, A., Dold, S. M., Zweegman, S., Terpos, E., Wäsch, R., D’Agostino, M., Scheubeck, S., Goldschmidt, H., Gay, F., Cavo, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0142-9 · Cited by 110
“[14] 4-week cycles R: 25 mg/d d1-21 d: 40 mg d 1,8,15,22 6-week cycles M: 0.”
BackgroundSelf-citationThe safety of bortezomib for the treatment of multiple myeloma
Cengiz Seval, G., & Beksac, M. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1513487 · Cited by 117
“After these results, lenalidomide-dexamethasone (Rd) becomes accepted as a standard treatment option for transplant-ineligible patients depending on the results of the FIRST phase III trial [34].”
BackgroundFacon, T., Venner, C. P., Bahlis, N. J., Offner, F., White, D. J., Karlin, L., Benboubker, L., Rigaudeau, S., Rodon, P., Voog, E., et al. (2021) · Blood · doi:10.1182/blood.2020008787 · Cited by 104
Self-citationElderly patients with multiple myeloma: towards a frailty approach?
Zweegman, S., Engelhardt, M. M., & Larocca, A. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000395 · Cited by 102
“Recently, the results from the FIRST-trial showed superiority of lenalidomide/dexamethasone over MPT both with respect to PFS and OS [12].”
ResultLudwig, H., Delforge, M., Facon, T. T. F., Einsele, H., Gay, F., Moreau, P., Avet‐Loiseau, H., Boccadoro, M., Hájek, R., Mohty, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0040-1 · Cited by 104
“Grade 3 and 4 infections were noted in 29% of patients treated with continuous lenalidomide–dexamethasone [21] and in 16.”
BackgroundSelf-citationEuropean Perspective on Multiple Myeloma Treatment Strategies in 2014
Ludwig, H., Sonneveld, P., Davies, F. E., Bladé, J., Boccadoro, M., Cavo, M., Morgan, G. J., de la Rubia, J., Delforge, M., Dimopoulos, M. A., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0042 · Cited by 102
Self-citationMagarotto, V., Bringhen, S., Offidani, M., Benevolo, G., Patriarca, F. F., Mina, R., Falcone, A. P., Paoli, L. D., Pietrantuono, G., Gentili, S., et al. (2016) · Blood · doi:10.1182/blood-2015-08-662627 · Cited by 93
Efficace, F., Gaïdano, G., & Lo‐Coco, F. (2017) · Blood · doi:10.1182/blood-2017-03-737403 · Cited by 98
Shah, J. J., Abonour, R., Gasparetto, C., Hardin, J. W., TOOMEY, K. E., Narang, M., Srinivasan, S. S., Kitali, A., Zafar, F., Flick, E. D., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.06.013 · Cited by 99
Anderson, K. C., Auclair, D., Kelloff, G. J., Sigman, C. C., Avet‐Loiseau, H., Farrell, A. T., Gormley, N. J., Kumar, S. K., Landgren, O., Munshi, N. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2895 · Cited by 97
“In the FIRST trial (83) comparing 18 months of lenalidomide to lenalidomide until progression, PFS was superior for the indefinite lenalidomide, with no improvement in OS.”
MethodSelf-citationGiuliani, M., Janji, B., & Berchem, G. (2017) · OncoTarget · doi:10.18632/oncotarget.15234 · Cited by 83
Stewart, A. K., Jacobus, S. J., Fonseca, R., Weiss, M., Callander, N. S., Chanan-Khan, A. A., & Rajkumar, S. V. (2015) · Blood · doi:10.1182/blood-2014-12-613927 · Cited by 96
Delforge, M., Minuk, L. A., Eisenmann, J.-C., Arnulf, B., Canepa, L., Fragasso, A., Leyvraz, S., Langer, C., Ezaydi, Y., Vogl, D. T., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.120121 · Cited by 90
Self-citationPromising therapies in multiple myeloma
Bianchi, G., Richardson, P. G. G., & Anderson, K. C. (2015) · Blood · doi:10.1182/blood-2015-03-575365 · Cited by 93
Self-citationClinical pharmacokinetics and pharmacodynamics of lenalidomide
Chen, N., Zhou, S., & Palmisano, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0432-1 · Cited by 86
Song, X., Cong, Z., & Wilson, K. L. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1105202 · Cited by 84
Hulin, C., Belch, A. R., Shustik, C., Petrucci, M. T., Dührsen, U., Lu, J., Song, K., Rodon, P., Pegourié, B., Garderet, L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7295 · Cited by 88
Self-citationCook, G., Larocca, A., Facon, T. T. F., Zweegman, S., & Engelhardt, M. M. (2020) · Leukemia · doi:10.1038/s41375-020-0918-6 · Cited by 92
Self-citationLarocca, A., Bonello, F., Gaïdano, G., D’Agostino, M., Offidani, M., Cascavilla, N., Capra, A., Benevolo, G., Tosi, P., Galli, M., et al. (2021) · Blood · doi:10.1182/blood.2020009507 · Cited by 95
“There is no evidence that lenalidomide improves the outcome of patients with high-risk cytogenetics; 2,23 triplets or more intensive regimens including newer drugs 5,6,24 are needed to overcome their bad prognosis.”
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
Rajkumar, S. V., & Harousseau, J. L. (2016) · Blood · doi:10.1182/blood-2016-09-692947 · Cited by 84
Jones, J. R., Cairns, D. A., Gregory, W. M., Collett, C., Pawlyn, C., Sigsworth, R., Striha, A., Henderson, R., Kaiser, M., Jenner, M. W., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.114 · Cited by 85
How I treat myeloma with new agents
Moreau, P. (2017) · Blood · doi:10.1182/blood-2017-05-743203 · Cited by 87
Self-citationInflammasome inhibitors: promising therapeutic approaches against cancer
Xu, S., Li, X., Liu, Y., Xia, Y., Chang, R., & Zhang, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0755-0 · Cited by 86
Dimopoulos, M. A., Špıčka, I., Quach, H., Oriol, A., Hájek, R., Garg, M. K., Beksaç, M., Bringhen, S., Katodritou, E., Chng, W. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02060 · Cited by 84
Self-citationGarderet, L., Beohou, E., Caillot, D., Stoppa, A. M., Touzeau, C., Chrétien, M. L., Karlin, L., Moreau, P., Fontan, J., Blaise, D., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.150334 · Cited by 82
“8%) Bone marrow aspirate: % plasmacytosis Median (range) 40(7-90) 36(4-72) 37(4-90) 0.”
Self-citationMoreau, P., Joshua, D. E., Chng, W.-J., Palumbo, A. P., Goldschmidt, H., Hájek, R., Facon, T. T. F., Ludwig, H., Pour, L., Niesvizky, R., et al. (2016) · Leukemia · doi:10.1038/leu.2016.186 · Cited by 87
Self-citationCarfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Jasielec, J. K., Kubicki, T., Raje, N. S., Vij, R., Reece, D. E., Berdeja, J. G., Derman, B. A., Rosenbaum, C. A., Richardson, P. G. G., Gurbuxani, S. K., et al. (2020) · Blood · doi:10.1182/blood.2020007522 · Cited by 75
How I treat fragile myeloma patients
Larocca, A., & Palumbo, A. P. (2015) · Blood · doi:10.1182/blood-2015-05-612960 · Cited by 79
“Recently, Rd continuously was shown to be more effective than MPT at diagnosis.(32) Of note, currently approved combinations were validated in studies that included highly selected elderly patients, and a geriatric evaluation was not performed.”
MethodResultInfluentialMultiple Myeloma, Version 2.2016
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C. L., Djulbegović, B., Fung, H. C. H., Gasparetto, C., Godby, K. N., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0167 · Cited by 85
Self-citationHow I treat multiple myeloma in geriatric patients
Facon, T. T. F., Leleu, X. P., & Manier, S. (2023) · Blood · doi:10.1182/blood.2022017635 · Cited by 79
Self-citationDumontet, C., Hulin, C., Dimopoulos, M. A., Belch, A. R., Dispenzieri, A. A., Ludwig, H., Rodon, P., Droogenbroeck, J. V., Qiu, L., Cavo, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0133-x · Cited by 77
“The FIRST study (MM-020/IFM07-01; NCT00689936) has been previously reported [7].”
BackgroundMethodInfluentialSelf-citationBerdeja, J. G., Jagannath, S., Zonder, J. A., Badros, A. Z., Kaufman, J. L., Manges, R., Gupta, M., Tendolkar, A. V., Lynch, M. J., Bleickardt, E. W., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.12.007 · Cited by 70
Orlowski, R. Z., Moreau, P., Niesvizky, R., Ludwig, H., Oriol, A., Chng, W. J., Goldschmidt, H., Yang, Z., Kimball, A. S., & Dimopoulos, M. A. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.04.018 · Cited by 74
Self-citationBiase, S. D., Shim, H. S., Kim, K. H., Vinciguerra, M., Rappa, F., Wei, M., Brandhorst, S., Cappello, F., Mirzaei, H., Lee, C. D., et al. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2001951 · Cited by 79
Metadata
- Authors
- Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J.-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., & Facon, T.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Mayo Clinic (US)
- Frankston Hospital (AU)
- University of Alberta (CA)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Tübingen (DE)
- Wilhelminen Hospital (AT)
- University of Calgary (CA)
- Centre Hospitalier de la Côte Basque (FR)
- Universitair Ziekenhuis Leuven (BE)
- St Bartholomew's Hospital (GB)
- Unidade Local de Saúde de Coimbra (PT)
- Chonnam National University Hwasun Hospital (KR)
- Princess Margaret Cancer Centre (CA)
- Josep Carreras Leukaemia Research Institute (ES)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Dalhousie University (CA)
- Kantonsspital Winterthur (CH)
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Louis (FR)
- Hôpital Purpan (FR)
- Celgene (United States) (US)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- ORCID
- Benboubker, Lotfi
- Dimopoulos, Meletios A.
- Dispenzieri, Angela
- Belch, Andrew R.
- Weisel, Katja
- Ludwig, Heinz
- Bahlis, Nizar
- Banos, Anne
- Geraldes, Catarina
- Lee, Je-Jung
- Chen, Christine
- Oriol, Albert
- Qiu, Lugui
- White, Darrell J.
- Anderson, Kenneth
- Fermand, Jean-Paul
- Moreau, Philippe
- Attal, Michel
- Knight, Robert
- Chen, Guang
- Jacques, Christian
- Hulin, Cyrille
- Facon, Thierry
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-04
- Volume
- 371
- Issue
- 10
- Pages
- 906-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141105112
- Cited by
- 793
- References
- 38
- Citations by year
- 2026: 18 · 2025: 41 · 2024: 39 · 2023: 37 · 2022: 54 · 2021: 74 · 2020: 89 · 2019: 75 · 2018: 80 · 2017: 92 · 2016: 102 · 2015: 76 · 2014: 15
- FWCI
- 67.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- lenalidomide, dexamethasone, multiple myeloma, transplant-ineligible patients, progression-free survival, overall survival, treatment duration, adverse events, second primary malignancy, infection, neurotoxicity, hematologic toxicity, newly diagnosed multiple myeloma
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prednisone, Thalidomide, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.